Antiprotozoal drugs in the treatment of respiratory allergy: a side that should be explored Rafael Martínez-Girón Respiratory allergy is one of the most chronic airway diseases and a major health problem worldwide because of its prevalence, considerable impact on quality of life, disproportionate share of healthcare resources and economic burden. Besides factors such as genetic predisposition, environmental contaminants and biological aeroallergens (pollen, fungi, dust mites), the role of certain microorganisms (respiratory viruses such as respiratory syncytial virus and rhinovirus, and atypical bacteria like Mycoplasma pneumoniae and Chlamydophila pneumoniae) on both the development and the severity of respiratory allergy is a subject of continuous debate.
On the other hand, a possible relationship between protozoa and respiratory allergy, taking into account certain aspects such as the presence of protozoa in intestinal extracts of house dust mites, their entrance to the airways through inhaled mite faeces, and their role as triggers of respiratory allergy, has been recently postulated [Martínez-Giró n and van Woerden, in press].
Uncommon multiflagellated protozoa have been described in the sputum of asthmatic patients, nasal secretions of patients with allergic rhinitis, and sputa of immunodepressed patients [Martínez-Giró n et al. 2008] , and certain bronchopulmonary infections provoked by these multiflagellated protozoa in immunodepressed patients (mainly transplants and AIDS) that have responded favourably to metronidazole therapy, have been reported in the literature [Ribas et al. 2007 ].
Also, an interesting topic concerning the use of metronidazole in the respiratory apparatus and its effectiveness in the treatment of pulmonary acariasis (presence of mites in the lungs and demonstrated by its observation in the sputum), has been discussed [Xia et al. 2005] . It is possible that the existence of protozoa in the gut of these arthropods may play some role in the favourable therapeutic response. Although different therapeutic options are available for respiratory allergy, it is still a chronic and incurable disease characterized by exacerbations and, in some cases, adverse effects of medicaments.
There has been a call of attention to the need for change in asthma management, including a better understanding of the inflammatory component in the assessment of treatment efficacy [Holgate et al. 2008 ]. This declaration and the above considerations leads one to think that the use of antiprotozoal drugs in the treatment of respiratory allergy is a side that should be explored. This matter is important because a number of existing antiprotozoal chemotherapeutic agents could be explored as treatment for related allergic conditions (mainly allergic rhinitis and bronchial asthma), to design tools for diagnosis and immunotherapy. The development of additional clinical essays with antiprotozoal drugs in a great number of patients and control individuals would be essential in the approach that professionals such as pneumologists, allergists, and ear nose and throat specialists take from now on in order to assess this topic.
